Clinical trials: Left Heart Failure
Heart Failure
AI-Guided Left Bundle Branch Area Pacing
The purpose of this study is to compare the effectiveness of AI-guided LBBAP versus conventional LBBAP (not AI-guided) in improving CRT response rates and clinical outcomes.
- Trial name
- NCT07206602
- Testing
- AI-assisted Left Bundle Branch Area Pacing, Left Bundle Branch Area Pacing
- Where
- United States
- Volunteers
- 224 people
- Sponsor
- Mayo Clinic
Chronic Kidney Disease 5D, Heart Failure
Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction
This is a single-arm cohort study aimed to evaluate change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a…
- Conditions
- Chronic Kidney Disease 5D, Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II
- Trial name
- NCT06394986
- Testing
- Hemodialysis session
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Hypertension, Pulmonary, Ventricular Dysfunction, Left
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction
The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic dysfunction
- Trial name
- DILATE (NCT01172756)
- Testing
- Riociguat (BAY63-2521)
- Where
- 7 sites in Austria, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Bayer
Heart Failure
Left Ventricular Lead Position in Cardiac Resynchronization Therapy
Left ventricular (LV) lead position has crucial impact on cardiac resynchronization therapy (CRT) success. This study will compare fluoroscopy and myocardial deformation imaging for optimal definition of LV lead position.
- Trial name
- NCT00748735
- Testing
- Implantation of a cardiac resynchronization therapy device, Echocardiography (myocardial deformation imaging)
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- RWTH Aachen University
Heart Failure, Cardiomyopathy
Correlating QLV Interval to Left Ventricular (LV) Lead Position in Patients Receiving Cardiac Resynchronization Therapy.
This is a prospective clinical trial to determine the optimal QLV interval during implantation to achieve the best possible response from cardiac resynchronization therapy for heart failure patients.
- Conditions
- Heart Failure, Cardiomyopathy, Cardiac Arrhythmia
- Trial name
- QLV (NCT02166762)
- Testing
- QLV interval measurement
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Heart Failure
Activity at Pulse Pressure Above an Individual Threshold in Patients With LVAD
Pilot study in patients with continuous flow left ventricular assist device (cfLVAD) to proof the feasibility of a specific individual training at home aimed to increase pulse pressure above a predefined threshold which might…
- Trial name
- NCT02304965
- Testing
- Daily physical activity
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Hannover Medical School
Heart Failure
Evaluation of Left Ventricular (LV) Lead Positioning Using MediGuide
The purpose of this study is to evaluate Cardiac Resynchronization Therapy(CRT) response in subjects with concordant versus discordant left ventricular (LV) lead position as compared to the site of latest mechanical activation.
- Trial name
- NCT01917266
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Cardiovascular Diseases
Novel INXN-4001 Triple Effector Plasmid in Heart Failure
To evaluate the safety of retrograde coronary sinus infusion (RCSI) of a novel triple-effector plasmid (INXN-4001) in outpatient LVAD recipients as assessed by incidence of all study intervention-related adverse events occurring…
- Conditions
- Heart Failure, Cardiovascular Diseases, Heart-Assist Device
- Trial name
- NCT03409627
- Testing
- INXN-4001
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Triple-Gene, LLC
Bradycardia, Heart Failure
LEft Bundle branchArea Pacing to Avoid Pacing-induced CARdiomyopathy
LEAP-CAR will evaluate the benefit of left bundle branch area pacing (LBBAP), comparing to conventional right ventricular pacing (RVP), in preventing pacing-induced cardiomyopathy (PICM) in patients undergoing pacemaker implant…
- Conditions
- Bradycardia, Heart Failure, Pacemaker-Induced Cardiomyopathy, Conduction Block, Atrioventricular
- Trial name
- LEAP-CAR (NCT05910866)
- Testing
- Left bundle branch area pacing (LBBAP), Right ventricular pacing (RVP)
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation
The Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation (EVENT) was designed to examine the hypothesis that, compared with placebo, therapy with the SGLT2 inhibitor enavogliflozin would improve clinical and…
- Trial name
- EVENT (NCT06027307)
- Testing
- Enavogliflozin
- Where
- 5 sites in South Korea
- Volunteers
- 541 people
- Sponsor
- Asan Medical Center
Heart Failure With Reduced Ejection Fraction
Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure
This a single-center, retrospective, observational study of patients that undergo coronary sinus(CS) lead revision, comparing epicardial lead placement to coronary sinus pacing(CSP) in those that had lead failure.
- Trial name
- NCT06342492
- Testing
- Coronary Sinus Lead Revision
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Kansas City Heart Rhythm Research Foundation
Heart Failure
ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure…
- Trial name
- NCT07379788
- Testing
- Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO], Empagliflozin10Mg Tab
- Where
- Saudi Arabia
- Volunteers
- 180 people
- Sponsor
- Rehab Werida
Chronic Kidney Disease, Left Ventricular Hypertrophy
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
To evaluate the effects of paricalcitol capsules on cardiac structure and function over 48 weeks in patients with Stage 3/4 chronic kidney disease (CKD) who had left ventricular hypertrophy (LVH).
- Trial name
- PRIMO (NCT00497146)
- Testing
- paricalcitol
- Where
- 71 sites in United States, Australia and 10 more
- Volunteers
- 227 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Diseases, Cardio-Renal Syndrome
Left Ventricular Fibrosis in Chronic Kidney Disease
This study aims to understand the onset an functional consequences of left ventricular interstitial fibrosis in patients with chronic kidney disease (stage 2 to 5), as well as assess whether transplantation results in a…
- Conditions
- Chronic Kidney Diseases, Cardio-Renal Syndrome, Myocardial Fibrosis, Uraemic Cardiomyopathy
- Trial name
- FibroCKD (NCT03176862)
- Testing
- cardiac magnetic resonance scan, Cardiopulmonary exercise test with stress echocardiogram, 24-hour ECG holter monitor
- Where
- United Kingdom
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Dr Manvir Kaur Hayer
Diastolic Dysfunction, Heart Failure
Assessment of Diastolic Function in High Risk Patients Undergoing Major Vascular Surgery
Patients scheduled for Thoracic Endovascular Aortic Repair (TEVAR) surgery will have transthoracic echocardiography evaluation of left ventricle diastolic function during the perioperative period.
- Conditions
- Diastolic Dysfunction, Heart Failure, Aneurysm Aortic
- Trial name
- NCT03534440
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Medical University of Warsaw
Heart Failure
Predictors of an Unfavorable Outcome in Patients With Heart Failure
The subject of the study is the factors of unfavorable prognosis in heart failure. We would like to identify independent variables associated with a bad prognosis of patients hospitalized for heart failure with a reduced vs.
- Trial name
- NCT04753814
- Testing
- Diagostic tests
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Polish Mother Memorial Hospital Research Institute
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF
US Benchmarking Clinical Study
The goal of this observational study is to measure shear wave velocity (SWV) in patients with non-reduced left ventricular ejection fraction (LVEF) heart failure and left ventricular hypertrophy, with or without transthyretin…
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy
- Trial name
- EMS-CT-1 (NCT07215715)
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- eMyosound SAS
Heart Failure
Heart Failure Ventricular Pressure Time Profile
This proposed study aim to: 1. Determine intra-LV pressure-time profile non-invasively using recently developed echo Doppler VFM analysis and applanation tonometry and myocardial elastic properties, in HF subjects (both HFNEF and…
- Trial name
- HF-VFM (NCT02791074)
- Testing
- NTproBNP, Echocardiography, Arterial tonometry
- Where
- Singapore
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Heart Centre Singapore
Heart Failure, Cardiac Resynchronization Therapy
Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy
The primary objective of this study is to assess the chronic safety and performance of the Axone left ventricular (LV) micro-lead.
- Trial name
- ASTRAL-4LV (NCT04463641)
- Testing
- Implantation of the Axone 4LV Lead
- Where
- 21 sites in Austria, France and 5 more
- Volunteers
- 92 people
- Sponsor
- MicroPort CRM
Myocardial Infarction
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
- Trial name
- ALLSTAR (NCT01458405)
- Testing
- CAP-1002 Allogeneic Cardiosphere-Derived Cells
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Capricor Inc.